Perez Daniel Antonio sold $411K of HNGE

Perez Daniel Antonio (CEO & Co-Founder) sold 4,100 shares of Hinge Health, Inc. (HNGE) at $100.20 ($0.41M total) on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Perez Daniel Antonio
Published Oct 8, 2026, 1:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HNGE
Bearish
medium confidence
Mentioned
$HNGE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGEBearishLow
01

Why it matters

The filing provides fresh data on insider holdings, which can affect short‑term sentiment.

02

Market read

First public disclosure of a CEO's complete divestiture, modest in size but potentially sentiment‑driving.

03

What to watch

The price per share ($100.20) was near recent trading levels, suggesting no discount.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses insider transactions required by regulators.

Company-level read

Ticker impact

$HNGEBearishMedium confidence
Context

CEO Perez Daniel Antonio sold all 4,100 shares for $410,811 via a 10b5-1 plan, reducing his stake to zero.

Expected impact

likely downward pressure as investors price in the insider sell

Evidence & confidence

A 10b5-1 sale by the CEO, even at a modest amount, often triggers short-term sell‑offs.

Market effects

Minimal impact on the broader digital health sector.

Limited to U.S. investors tracking Hinge Health.

None

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Hinge Health, Inc.

    Digital health platform listed on NASDAQ under ticker HNGE.

  • Perez Daniel Antonio

    CEO & Co‑Founder of Hinge Health, 10% owner.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HNGEHighAI 8/10

Needham raises Hinge Health stock price target on client growth

Needham raised its price target for Hinge Health (NYSE:HNGE) to $135 from $115, citing strong client growth and quarterly performance. The company reported 28% year-over-year client growth, 50% revenue increase, and 154% stock return over six months. Q3 revenue was $235 million, up 52% year-over-year, with EPS of $0.66 beating estimates. Wells Fargo also raised its target to $132, noting strong margins and revenue growth.

$HNGEHighAI 8/10

Hinge Health (HNGE) Q3 2026 Earnings Call Transcript

Hinge Health (HNGE) reported Q3 2026 revenue of $235M, up 52% YoY, with gross margin at 88% and operating income at $77M. The company highlighted growth in its MSK, Migraine, and GI care programs, with strong early results in Migraine care. President Jim Pursley announced his departure at year-end to spend more time with family but will join the board.